Drug Profile
Research programme: neurodegenerative disease therapeutics - Denali Therapeutics/F-star Therapeutics
Latest Information Update: 09 Mar 2023
Price :
$50
*
At a glance
- Originator Denali Therapeutics Inc; f-star
- Developer Denali Therapeutics Inc; F-star Therapeutics
- Class Bispecific antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neurodegenerative disorders
Most Recent Events
- 09 Mar 2023 F-star Therapeutics has been acquired by invoX Pharma
- 20 Nov 2020 Spring Bank Pharmaceuticals has merged with F-star to form F-star Therapeutics
- 28 Sep 2020 No recent reports of development identified for research development in Neurodegenerative-disorders in France (Parenteral)